Ursodeoxycholic acid is associated with a reduction in SARS-CoV-2 infection and reduced severity of COVID-19 in patients with cirrhosis
Graphical Abstract Sample Work
COVID-19 remains a significant risk for patients with cirrhosis, who face higher mortality and limited safe treatment options due to hepatotoxicity of existing drugs. Vaccines show reduced effectiveness in immunocompromised individuals and emerging variants. Ursodeoxycholic acid (UDCA), an FXR inhibitor, has been shown to reduce ACE2 expression and may help prevent SARS-CoV-2 infection and severity. This study evaluates the association between UDCA use and COVID-19 outcomes in patients with cirrhosis.
Give yourself the academic edge today
Each order includes
- On-time delivery or your money back
- A fully qualified writer in your subject
- In-depth proofreading by our Quality Control Team
- 100% confidentiality, the work is never re-sold or published
- Standard 7-day amendment period
- A paper written to the standard ordered
- A detailed plagiarism report
- A comprehensive quality report